Article

Quality of life and anxiety disorders: a population study.

Department of Psychology, University of Oslo, Oslo, Norway.
Journal of Nervous & Mental Disease (Impact Factor: 1.81). 04/2005; 193(3):196-202. DOI: 10.1097/01.nmd.0000154836.22687.13
Source: PubMed

ABSTRACT The study of quality of life has increased in importance in the area of mental disorders during the last decade. The aim of the present study was to investigate the effect of specific anxiety disorders on specific quality of life indicators in the common population. More than 2000 individuals between 18 and 65 years old were studied by means of structured interviews. The results showed that social phobia and panic disorder within the past year and lifetime, and generalized anxiety disorder within the past year, had an independent effect on quality of life when controlling for a number of sociodemographic variables, somatic health, and other DSM-III-R Axis I mental disorders. Specific phobias and obsessive compulsive disorder had only a small effect, and agoraphobia showed no effect. The effect was strongest for self-realization and contact with friends, but anxiety disorders also influenced subjective well-being, social support, negative life events, contact with family of origin, and neighborhood quality.

1 Follower
 · 
199 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to examine whether anxiety sensitivity and agoraphobic fear could affect the time taken to remission after 24 weeks of open-label escitalopram treatment of patients with panic disorder (PD). We recruited 158 patients, and 101 patients completed the study. Clinical severity and psychological characteristics were assessed at baseline and 4, 12, and 24 weeks after the treatment, using the Clinical Global Impression-Severity (CGI-S), the Hamilton Rating Scales for Anxiety and Depression, the Anxiety Sensitivity Index-Revised (ASI-R), the Albany Panic and Phobia Questionnaire (APPQ), and the Panic Disorder Severity Scale (PDSS). Remission was defined as the absence of full panic attacks and PDSS scores of 7 or less. Completing patients were stratified according to the time taken to remit: early (n=20) and late (n=58) remission and non-remission groups (n=23). There were no significant differences among the three groups at baseline on the CGI-S and the PDSS mean scores. However, early remitters had significantly lower scores than late remitters and non-remitters on the ASI-R and APPQ. In conclusion, anxiety sensitivity and agoraphobic fear can affect the time to remission after pharmacotherapy, and clinicians should consider the psychological characteristics of PD patients in order to achieve an optimal response to pharmacotherapy.
    Psychiatry Research 02/2012; 197(3):237-41. DOI:10.1016/j.psychres.2011.11.001 · 2.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Data from a relapse prevention study of duloxetine treatment for adults with generalized anxiety disorder (GAD) were examined to identify predictors of relapse. Patients responding to 6 months of open-label duloxetine treatment were randomized to continuation with duloxetine or withdrawal to placebo for a 6-month double-blind continuation phase (duloxetine, N= 216; placebo, N= 213). Post hoc analyses compared time to GAD relapse during continuation phase by using predictor variables that included patient demographics, symptom severity measures (Hamilton Anxiety Scale Scores [HAMA], Hospital Anxiety and Depression Scale), functional outcomes, and visual analogue scale (VAS) pain measures. Univariate and multivariate analyses were performed using predictor variables from time of randomization into the continuation, withdrawal phase. Severity of anxiety symptoms, degree of functional impairment, and severity of pain at time of randomization were significantly predictive of likelihood of relapse during the continuation phase. Multivariate backwards elimination analysis of significant univariate predictors identified HAMA item one (anxious mood) ≥ 1 and severity of pain while awake (≥ 30 on VAS) as the strongest predictors of GAD relapse. For patients with GAD responding to open-label treatment with duloxetine, residual symptoms related to anxious mood, pain severity, and psychosocial function were associated with increased relapse risk, although the greatest risk was associated with anxious mood and increased severity of pain while awake.
    Human Psychopharmacology Clinical and Experimental 06/2011; 26(3):258-66. DOI:10.1002/hup.1211 · 1.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this paper is to assess the subjective well-being of chronically ill inpatients to know which its influential factors are, what the significant predictors of SWB are, and what we can do in nursing care. A sample of 290 inpatients with chronic respiratory diseases, diabetes, and cardiovascular diseases responded to questionnaires assessing well-being, anxiety, and depression and gave suggestions about nursing during an interview. It was shown that these patients' subjective well-being was lower than that of the general population. Using ANOVA, Pearson correlations, and multivariate stepwise regression analysis, trait anxiety, anxiety, and means of payment were found to significantly influence subjective well-being. Interventions targeting trait anxiety, anxiety, and means of payments, such as paying more attention to individuals' psychological symptoms, implementing more cost-effective treatment or caring, and establishing positive relationship with patients are necessary to improve inpatients' subjective well-being.
    Applied nursing research: ANR 11/2009; 22(4):250-7. DOI:10.1016/j.apnr.2008.02.005 · 1.14 Impact Factor